Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896984 · ClinicalTrials.gov registry record
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 346
- Enrollment target
NCT03896984: Completed study, sponsored by Bayer.
NCT03896984 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 346 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03896984 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 346 participants
- Enrollment target
Study Summary
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH therapy (first line treatment). Additionally the researchers are also interested in the occurrence of bone fractures and other skeletal events. Basis for this study will be the US based Flatiron database which provides access to clinical data for cancer patients.
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Radium-223 (Xofigo, BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2020-12-14 |
What the finished NCT03896984 record still lists
NCT03896984 is an observational study that tracks outcomes without assigning an intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Enzalutamide is the first listed.
NCT03896984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03896984 about?
NCT03896984 is a clinical study titled "Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).". In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy (NAH) or Radium-223 (Xofigo) after a prior NAH therapy (first line tre...
What is the current status of trial NCT03896984?
This trial is currently completed. The enrollment target is 346 participants. The study started on 2019-03-18. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT03896984?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), Radium-223 (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT03896984?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI